• Sun. Sep 17th, 2023

Two Indicted for Fentanyl Plot

Avatar photo

ByDavid Brown

Sep 17, 2023
Two Indicted for Fentanyl Plot
David Brown
Latest posts by David Brown (see all)

In Boston, two men from New Bedford are being prosecuted on federal allegations of selling fentanyl and stealing identities. Vinicio DeJesus Marrero Arias, 39, and Yohenry Contreras-Lara, 29, were charged with conspiring to distribute more than 400 grams of fentanyl. Additional accusations against Contreras-Lara include aggravated identity theft and misuse of a social security number.

Crackdown on Fentanyl Distributors: Charges and Consequences

Acting US Attorney Joshua S. Levy praised collaborations with local law enforcement while emphasizing the continued battle against the destruction fentanyl has wrought in Massachusetts.

The DEA’s Brian D. Boyle underscored the risks posed by fentanyl and the agency’s dedication to going after those responsible for its distribution.

The necessity of prosecuting people who misuse social security numbers was stressed.

Contreras-Lara, who arrived in the US in 2002 on a tourist visa, is accused of buying a fake identity and living under it for years, even going so far as to seek for two Massachusetts driver’s licenses in 2022.

The indictment claims that Contreras-Lara and Arias were operating a fentanyl distribution business in the New Bedford area. After searches of their residences and other locations, more than 800 grams of fentanyl and $1.2 million in claimed drug proceeds were discovered.

There are severe punishments for the offenses. The maximum sentence for the conspiracy accusation is life in prison, the maximum sentence for the abuse of a social security number is five years, and the maximum sentence for the aggravated identity theft offense is two more years.

The defendants are presumed innocent unless and unless they are proven guilty in court beyond a reasonable doubt on the charges included in the indictment.

Avatar photo

David Brown

With years of expertise in the field, i am bring a wealth of knowledge and insights to our platform. Our editor’s extensive research and understanding of the drug landscape ensure that their content is accurate, informative, and engaging.